PIK3CA and neoplasm: Nevertheless, we show that treating patients with BRAFV600E inhibitors such as vemurafenib could be a valid approach in the appropriate clinical setting including prior mutational testing of the tumor and, if applicable, administered alone or combined with PI3’K inhibitors.